INTRABIOTICS (IBPI)------AM MONTAG BLUTBAD???????? - 500 Beiträge pro Seite

[SCARFACE13]

Friday May 3, 5:43 pm Eastern Time
Reuters Company News
Intrabiotics` mucositis drug ineffective in trial

MOUNTAIN VIEW, Calif., May 3 (Reuters) - Drug developer IntraBiotics Pharmaceuticals Inc. (NasdaqNM:IBPI - news) said on Friday that its experimental drug for limiting mouth sores in cancer patients undergoing radiation treatment failed to prove effective in a pivotal-stage trial.

The Mountain View, California-based company said initial results of its 545-patient Phase III clinical trial showed no difference between the drug, called iseganan hydrochloride oral solution, and placebo.

Both the group of patients who received iseganan and the group of patients who received placebo did better than the group of patients who received only standard of care, according to IntraBiotics.

The company said it is still in the process of analyzing and evaluating the data and will continue a Phase III trial of the drug in cancer patients undergoing high-dose chemotherapy.




AGGRESSIVE SELL IBPI


AL PACINO

[js200]

@Scarface

WARUM ?????

JS200

[SCARFACE13]

OUCH

-70%!!!!!



AL PACINO

[Ariminios]

AL DER GURU

[suxxx]

das ist das aus für intrabiotics nachbörslich -70%!!!!!!



IntraBiotics` antiobiotic failed to meet endpoint
Friday September 27, 4:58 pm ET


MOUNTAIN VIEW, Calif., Sept 27 (Reuters) - IntraBiotics Pharmaceuticals Inc. (NasdaqNM:IBPI - News) on Friday said its lead product, iseganan hydrochloride, failed to reduce the incidence and severity of mouth lesions in patients undergoing high-dose chemotherapy.
ADVERTISEMENT


According to preliminary results from the company`s 509-patient Phase III clinical trial, 43 percent of patients taking iseganan did not develop severe ulcerative oral mucositis, compared with 37 percent of patients in the placebo group, a difference that did not reach statistical significance.

"While iseganan appeared to show some benefit in this patient setting, the benefit was not statistically significant. As a result, we will cease the pursuit of severe oral mucositis as an indication for iseganan," Dr. Ernest Mario, IntraBiotics chairman and chief executive, said in a statement.

IntraBiotics shares, which ended the regular Nasdaq session down 18 cents at $1.57, fell to 80 cents in after-hours trading on Instinet.

[Lekrud]

Puh...Und ich wollte vorhin noch bei 1,50 einsteigen,hatte mich aber zum Glück doch für Lucent entschieden!

Mal schauen ob ich Montag oder Dienstag reingehe!

[js200]

18.20 $ 0.54 430
18.20 $ 0.53 500
18.05 $ 0.54 750
17.52 $ 0.53 700
17.52 $ 0.53 300
17.52 $ 0.53 1000
17.36 $ 0.63 200
17.36 $ 0.63 5000
17.29 $ 0.55 200
17.29 $ 0.55 5000
17.16 $ 0.61 600
17.16 $ 0.61 900
17.16 $ 0.61 3400
17.11 $ 0.55 2000
17.10 $ 0.55 4000
17.06 $ 0.52 1400
17.06 $ 0.53 200
17.06 $ 0.52 2000
17.06 $ 0.52 1400
17.06 $ 0.52 2000
17.06 $ 0.53 200
17.02 $ 0.68 900
17.02 $ 0.66 100
16.59 $ 0.51 1400
16.59 $ 0.51 1000
16.57 $ 0.71 100
16.56 $ 0.71 1500
16.56 $ 0.71 500
16.56 $ 0.71 1000
16.52 $ 0.80 200
16.52 $ 0.80 200
16.52 $ 0.80 100
16.51 $ 0.80 200
16.51 $ 0.80 500
16.46 $ 1.32 200
16.45 $ 1.40 500


JS200

[js200]

company news

--------------------------------------------------------------------------------

IBPI - IntraBiotics Pharmaceuticals (NASDAQ NM : IBPI)

--------------------------------------------------------------------------------
PREMARKET: IBPI Announces Iseganan Study Results



MONDAY , SEPTEMBER 30, 2002 08:25 AM

IntraBiotics Pharmaceuticals (NasdaqNM: IBPI) issued a press release Friday afternoon to announce preliminary results of its Phase III clinical trail of iseganan hydrochloride oral solution, in reducing the incidence and severity of ulcerative oral mucositis in patients undergoing high-dose chemotherapy for the treatment of cancer.

According to the release, the results indicated that iseganan did not meet its primary endpoint of reducing oral mucositis.

JS200